Switch theme
Sign up to access all valuation multiples
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting global and internationally competitive investment targets, including new drug research and development, high-end medical equipment, innovative medical service technology, medical access, agricultural biotechnology.
2013
n/a
LTM Revenue n/a
LTM EBITDA n/a
$408M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diamond Biofund has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Diamond Biofund achieved revenue of n/a and an EBITDA of -$71.4M.
Diamond Biofund expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diamond Biofund valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$77.7M | -$71.4M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | $24.1M | -$78.0M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Diamond Biofund's stock price is TWD 22 (or $1).
Diamond Biofund has current market cap of TWD 18.5B (or $559M), and EV of TWD 13.5B (or $408M).
See Diamond Biofund trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $408M | $559M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Diamond Biofund has market cap of $559M and EV of $408M.
Diamond Biofund's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Diamond Biofund's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Diamond Biofund and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $408M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.7x | XXX | XXX | XXX |
| P/E | -7.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDiamond Biofund's NTM/LTM revenue growth is n/a
Diamond Biofund's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Diamond Biofund's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Diamond Biofund's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Diamond Biofund and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Investcorp Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| Waha Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| ASR Nederland | XXX | XXX | XXX | XXX | XXX | XXX |
| CVC Capital Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurocommercial Props | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diamond Biofund acquired XXX companies to date.
Last acquisition by Diamond Biofund was XXXXXXXX, XXXXX XXXXX XXXXXX . Diamond Biofund acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Diamond Biofund founded? | Diamond Biofund was founded in 2013. |
| Where is Diamond Biofund headquartered? | Diamond Biofund is headquartered in Taiwan. |
| Is Diamond Biofund publicy listed? | Yes, Diamond Biofund is a public company listed on TAI. |
| What is the stock symbol of Diamond Biofund? | Diamond Biofund trades under 6901 ticker. |
| When did Diamond Biofund go public? | Diamond Biofund went public in 2022. |
| Who are competitors of Diamond Biofund? | Similar companies to Diamond Biofund include e.g. Investcorp Capital, Waha Capital, ASR Nederland, CVC Capital Partners. |
| What is the current market cap of Diamond Biofund? | Diamond Biofund's current market cap is $559M |
| Is Diamond Biofund profitable? | Yes, Diamond Biofund is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
